Zoetis Hit with Class Action Over OA mAb Misrepresentations

What happened

A securities class action has been filed against Zoetis, alleging the company misled investors about weakening veterinarian adoption and prescription trends for its osteoarthritis monoclonal antibody franchise (Librela/Solensia) between January 2025 and May 2026. The lawsuit claims these misrepresentations artificially inflated the stock, which later dropped approximately $23.91 per share when the truth emerged. This legal development adds a new layer of risk to the existing operational headwinds identified in the DeepValue report, including safety concerns, slowing OA uptake, and livestock softness. While the class action is in its early stages, it increases the likelihood of settlement costs or adverse judgments, further pressuring the stock's recovery narrative. Investors should now weigh litigation risk alongside the company's fundamental challenges when assessing Zoetis's risk-reward profile.

Implication

The class action amplifies uncertainty around the OA franchise recovery and introduces potential financial liability, increasing the probability of the bear case scenario. Investors should incorporate litigation outcomes into their valuation models and monitor for discovery details that could reveal the extent of alleged misrepresentations.

Thesis delta

The securities class action shifts the risk profile from purely operational (OA adoption, competition) to include legal liability, which increases the probability of the bear case and lowers confidence in a quick recovery. Previously, the main risk was a slower OA ramp; now, legal costs and reputational damage could further impede growth and multiple expansion.